ArticleHealth affairs scholar2026
Association between integrated specialty pharmacy care model and pharmaceutical access and costs.
Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Health care consolidation in the United States has yielded mixed outcomes for patients; however, little is known about the impact of integration between insurers and specialty pharmacies. Through improved data and clinical integration, integrated specialty pharmacy care models may improve health care access and reduce costs for beneficiaries. However, this type of vertical integration may allow increased market power, which could lead to higher costs for beneficiaries. Methods: Using Humana prescription claims, our cross-sectional study used adjusted regression analyses evaluating the association between the use of an integrated specialty pharmacy care model with pharmaceutical access and costs for beneficiaries managing complex specialty conditions in 2024. Results: After adjusting for demographic and clinical characteristics, the integrated specialty pharmacy care model was associated with fewer days from prescription to fill (absolute difference: -5.7 days; 95% CI: -6.7 to -4.7 days) and, reduced yearly beneficiary pharmacy costs (-$106; 95% CI: -$163 to -$49) and yearly beneficiary costs for the specialty drug (-$77; 95% CI: -$129 to -$27) compared with nonintegrated specialty pharmacies. We found additional benefits for beneficiaries who also used integrated primary care services. Conclusion: Integrated specialty pharmacy care models may deliver faster and less costly pharmaceutical care for beneficiaries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.